MRG003 With Gemcitabine for Second-line Advanced PDAC
MRG003 With Gemcitabine for Second-line Advanced PDAC
Not yet recruiting · NCT07685470 · Registry updated 2026-07-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MRG003 With Gemcitabine for Second-line Advanced PDAC | Pancreatic Ductal Adenocarcinoma (PDAC); Second Line Treatment | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-06 | NCT07685470 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking Union Medical College Hospital | 417 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||